1
|
Li J, Hao Y, Liu Y, Wu L, Liang H, Ni L, Wang F, Wang S, Duan Y, Xu Q, Xiao J, Yang D, Gao G, Ding Y, Gao C, Xiao J, Zhao H. Supervised machine learning algorithms to predict the duration and risk of long-term hospitalization in HIV-infected individuals: a retrospective study. Front Public Health 2024; 11:1282324. [PMID: 38249414 PMCID: PMC10796994 DOI: 10.3389/fpubh.2023.1282324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 12/13/2023] [Indexed: 01/23/2024] Open
Abstract
Objective The study aimed to use supervised machine learning models to predict the length and risk of prolonged hospitalization in PLWHs to help physicians timely clinical intervention and avoid waste of health resources. Methods Regression models were established based on RF, KNN, SVM, and XGB to predict the length of hospital stay using RMSE, MAE, MAPE, and R2, while classification models were established based on RF, KNN, SVM, NN, and XGB to predict risk of prolonged hospital stay using accuracy, PPV, NPV, specificity, sensitivity, and kappa, and visualization evaluation based on AUROC, AUPRC, calibration curves and decision curves of all models were used for internally validation. Results In regression models, XGB model performed best in the internal validation (RMSE = 16.81, MAE = 10.39, MAPE = 0.98, R2 = 0.47) to predict the length of hospital stay, while in classification models, NN model presented good fitting and stable features and performed best in testing sets, with excellent accuracy (0.7623), PPV (0.7853), NPV (0.7092), sensitivity (0.8754), specificity (0.5882), and kappa (0.4672), and further visualization evaluation indicated that the largest AUROC (0.9779), AUPRC (0.773) and well-performed calibration curve and decision curve in the internal validation. Conclusion This study showed that XGB model was effective in predicting the length of hospital stay, while NN model was effective in predicting the risk of prolonged hospitalization in PLWH. Based on predictive models, an intelligent medical prediction system may be developed to effectively predict the length of stay and risk of HIV patients according to their medical records, which helped reduce the waste of healthcare resources.
Collapse
Affiliation(s)
- Jialu Li
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yiwei Hao
- Division of Medical Record and Statistics, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Ying Liu
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Wu
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongyuan Liang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Ni
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Fang Wang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Sa Wang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yujiao Duan
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Qiuhua Xu
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jinjing Xiao
- Department of Clinical Medicine, Zhengzhou University, Zhengzhou, China
| | - Di Yang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yi Ding
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Chengyu Gao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jiang Xiao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
2
|
Xiao J, Gao G, Ding Y, Li J, Gao C, Xu Q, Wu L, Liang H, Ni L, Wang F, Duan Y, Yang D, Zhao H. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients. Chin Med J (Engl) 2023; 136:2931-2937. [PMID: 38032036 PMCID: PMC10917078 DOI: 10.1097/cm9.0000000000002939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Indexed: 12/01/2023] Open
Abstract
BACKGROUND This study aimed to determine the reasons for conversion and elucidate the safety and efficacy of transition to tenofovir alafenamide/emtricitabine/bictegravir sodium (TAF/FTC/BIC) in highly active antiretroviral therapy (HAART)-experienced HIV-infected patients in real-world settings. METHODS We conducted a retrospective cohort study. The treatment conversion rationales, safety, and effectiveness in 1684 HIV-infected patients with previous HAART experience who switched to TAF/FTC/BIC were evaluated at Beijing Ditan Hospital from September 2021 to Auguest 2022. RESULTS Regimen simplification (990/1684, 58.79%) was the most common reason for switching, followed by osteoporosis or osteopenia (375/1684, 22.27%), liver dysfunction (231/1684, 13.72%), decline in tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat (TAF/FTC/EVG/c) with food restriction (215/1684, 12.77%), virological failure (116/1684, 6.89%), and renal dysfunction (90/1684, 5.34%). In patients receiving non-nucleotide reverse transcriptase inhibitors (NNRTI)-containing regimens, lipid panel changes 1 year after switching indicated a difference of 3.27 ± 1.10 mmol/L vs . 3.40 ± 1.59 mmol/L in triglyceride ( P = 0.014), 4.82 ± 0.74 mmol/L vs . 4.88 ± 0.72 mmol/L in total cholesterol ( P = 0.038), 3.09 ± 0.70 mmol/L vs . 3.18 ± 0.66 mmol/L in low-density lipoprotein ( P <0.001), and 0.99 ± 0.11 mmol/L vs . 0.95 ± 0.10 mmol/L in high-density lipoprotein ( P <0.001). Conversely, among patients receiving booster-containing regimens, including TAF/FTC/EVG/c and lopinavir/ritonavir (LPV/r), lipid panel changes presented decreased trends. We also observed an improved trend in viral load suppression, and alanine transaminase (ALT), aspartate transaminase (AST), estimated glomerular filtration rate (eGFR), and serum creatinine levels after the transition ( P <0.001). CONCLUSION The transition to TAF/FTC/BIC demonstrated good treatment potency. Furthermore, this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios, providing clinical evidence supporting the stable conversion to TAF/FTC/BIC for HAART-experienced patients.
Collapse
Affiliation(s)
- Jiang Xiao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Guiju Gao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Yi Ding
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Jialu Li
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Chengyu Gao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Qiuhua Xu
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Liang Wu
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Hongyuan Liang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Liang Ni
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Fang Wang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Yujiao Duan
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Di Yang
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| | - Hongxin Zhao
- Clinical and Research Center of AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
| |
Collapse
|
3
|
Mu X, Duan Y, Xu Q, Wang S, Gao G, Han N, Zhao H. Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report. Front Pharmacol 2023; 14:1268597. [PMID: 38027007 PMCID: PMC10643644 DOI: 10.3389/fphar.2023.1268597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 10/18/2023] [Indexed: 12/01/2023] Open
Abstract
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies. We describe a female patient with HIV, who was admitted to the emergency department following an unexplained loss of consciousness. This patient had been on antiretroviral therapy comprising tenofovir disoproxil fumarate, lamivudine, and lopinavir/ritonavir for 12 years. Coincidentally, she had been prescribed terfenadine for urticaria recently. After 3 days on this medication, she suddenly lost her consciousness, with a distinctive electrocardiogram alteration characterized by QT prolongation and torsade de pointes. This symptom recurred several times over a span of 2 days. We postulate that the primary instigator was an elevated concentration of terfenadine, which can be traced back to her antiretroviral therapy regimen comprising lopinavir/ritonavir. This drug is known to impede the metabolism of cytochrome P450 3A4 substrates and consequently elevate terfenadine concentrations.
Collapse
Affiliation(s)
- Xuechun Mu
- Emergency Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yujiao Duan
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Qiuhua Xu
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Sa Wang
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Ning Han
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Department of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
4
|
Rajeev-Kumar G, Manjunath R, Gao G, Hasan Y. Interdigitation of Radiation Earlier in the Multimodal Treatment of Patients with Lymphoma: The Effect on Opiate Analgesic Requirements. Int J Radiat Oncol Biol Phys 2023; 117:e482. [PMID: 37785528 DOI: 10.1016/j.ijrobp.2023.06.1705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Delay in radiation therapy (RT) as part of multimodality therapy in Hodgkin (HL) and non-Hodgkin lymphoma (NHL) is associated with worse pain scores. In a heterogeneous cohort of lymphoma patients, we hypothesize that interdigitating RT before fewer (versus more) lines of chemotherapy (C) will be associated with lower opiate analgesic requirement. MATERIALS/METHODS From 2009-2019, patients with HL or NHL received palliative (36.5%) or definitive (63.3%) RT at a single institution. An IRB approved database with baseline treatment/disease characteristics, including oral morphine equivalent (OME) requirement, was reviewed. OME was recorded for a) 3-month period prior to RT, b) the month during RT, and c) 3 months after RT. Post-RT change in OME was calculated as the difference in "b" and "c" such that greater or less OME use post-RT was defined as positive or negative value respectively. We performed one-tailed t-test analyses to determine differences in OME during RT between different cohorts. Correlations between baseline characteristics and OME were performed using Spearman correlations, controlling for lymphoma subtype, stage, tumor volume, relapsed/refractory disease, duration of radiation and bulky disease. RESULTS Of 180 patients, 57.8% had NHL, 40.6% were stage IV and 29.4% had bulky disease. At median of 19 days [6-80] from diagnosis, 74% of patients received C with a median of 2 lines [1-4] before RT. The median interval from diagnosis to RT was 11 months [4-36]. Pearson correlation showed a negative association between time from diagnosis to RT and postRT OME in the definitive cohort (R2 = 0.42, F = 4.54, p = 0.002) such that the longer the time to RT, the larger the decrease in OME postRT as compared to during RT. T-test showed higher mean OME during RT for those receiving > 2 lines of C preRT (148.3mg) as compared to those receiving ≤ 2 lines before RT (51.5mg, p = 0.02). In patients receiving definitive RT, the difference remained significant: those receiving >2 lines of C had higher OME during RT as compared to those receiving ≤ 2 lines (207.5mg versus 48.3mg, p = 0.02). The difference in mean OME for patients receiving >2 C lines versus ≤ 2 lines was not significantly different in the palliative cohort (75.6 vs 60.6, p = 0.33). OME use during RT was also found to be higher in patients with bulky disease as compared to non-bulky disease (175.7 versus 52.0, p = 0.04). CONCLUSION In our single-center experience, patients who received >2 lines of C prior to RT were found to have a significantly higher mean OME requirement during RT. In patients receiving definitive RT, longer time to receipt of RT was found to be associated with a larger decrease in OME post-RT, likely related to starting with a higher OME. Interdigitation of RT early on, prior to the 3rd line of chemotherapy, may help reduce pain and improve quality of life.
Collapse
Affiliation(s)
| | | | - G Gao
- University of Chicago, Chicago, IL
| | - Y Hasan
- Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL
| |
Collapse
|
5
|
Wang T, Liu Y, Zhu C, Yang S, Yang D, Xiao J, Gao G. Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients. Infect Drug Resist 2023; 16:4659-4666. [PMID: 37484907 PMCID: PMC10361278 DOI: 10.2147/idr.s415749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 07/01/2023] [Indexed: 07/25/2023] Open
Abstract
Background Rifampicin is a known inducer of the cytochrome P450 (CYP2B6) enzyme, which can lead to a decrease in the concentration of efavirenz. Therefore, we conducted a study to evaluate the effect of daily rifampicin intake on efavirenz 600mg pharmacokinetics and HIV-1 virological suppression. Methods Patients receiving antiretroviral therapy containing efavirenz (600mg daily), and we collected efavirenz concentration at four visit points: ART day 14 (PK1), ART day 42 (PK2), ART day 140 (PK3), and ART day 336 (PK4), and performed pharmacokinetics analysis. Results From February 2017 to November 2020, 29 HIV/TB co-infection patients were included. Ninety percent of patients had a concentration of ≥1000ng/mL of efavirenz during the study. All patients had efavirenz Cmax ≥1000ng/mL, 86% patients showed good virology response. Conclusion Our study shows that the use of rifampicin in HIV/TB co-infection patients does not affect efavirenz drug concentrations, that virological suppression is good and that no efavirenz dose adjustment is required.
Collapse
Affiliation(s)
- Tongtong Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Yingchu Liu
- School of General Practice and Continuing Education, Capital Medical University, Beijing, People’s Republic of China
| | - Chunyu Zhu
- Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Siyuan Yang
- Laboratory of Infectious Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
| |
Collapse
|
6
|
Zhao N, Xiang P, Zeng Z, Liang H, Wang F, Xiao J, Yang D, Wang S, Chen M, Gao G. Prevalence and risk factors for kidney disease among hospitalized PLWH in China. AIDS Res Ther 2023; 20:49. [PMID: 37454082 PMCID: PMC10349439 DOI: 10.1186/s12981-023-00546-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 07/08/2023] [Indexed: 07/18/2023] Open
Abstract
BACKGROUND Kidney disease is an important comorbidity in people living with HIV(PLWH), and is associated with poor outcomes. However, data on renal function of PLWH are limited in China so far. In this study we assessed the prevalence of kidney disease in patients either on antiretroviral therapy (ART) or not respectively in a single center in China and explored the possible risk factors associated. METHODS In the cross-sectional study, we recruited hospitalized adult PLWH. Demographic characteristics, clinical information and laboratory variables were collected. Kidney disease was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2, and/or isolated hematuria, proteinuria, microalbuminuria. We calculated the prevalence of kidney disease and used logistic regression to assess its associated risk factors. RESULTS A total of 501 adult PLWH were enrolled, 446 (89.0%) males and 55 (11.0%) females. The median age was 39 (IQR 30-50) years old. The prevalence of kidney disease was 19.0%, 22 (4.4%) patients with eGFR < 60 mL/min/1.73 m2, 53 (10.6%) patients with hematuria, 11 (2.2%) patients with proteinuria, and 40 (8.0%) patients with microalbuminuria. 297 (59.3%) patients were receiving ART. The patients on ART had a higher prevalence of renal disease than those had not been administrated with ART (22.6% vs. 13.7%, P = 0.013). On the multivariate logistic regression analysis among patients not on ART, lower haemoglobin (OR 0.994, 95%CI: 0.902-0.988, P = 0.013) were significantly associated with kidney disease. While among those on ART, older age (OR 1.034, 95%CI: 1.003-1.066, P = 0.032), lower haemoglobin (OR 0.968, 95%CI: 0.948-0.988, P = 0.002) and lower albumin (OR 0.912, 95%CI: 0.834-0.997, P = 0.044) were significantly associated with kidney disease. CONCLUSIONS The prevalence of kidney disease among hospitalized PLWH in China is high, especially in patients on ART. A larger scale study on Chinese outpatient PLWH should be conducted, so as to precisely assess prevalence of kidney disease in general Chinese PLWH.
Collapse
Affiliation(s)
- Naxin Zhao
- Department of Nephrology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Pan Xiang
- Department of Nephrology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Zhili Zeng
- Department of Nephrology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongyuan Liang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Fang Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Sa Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Meiling Chen
- Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
| |
Collapse
|
7
|
Su B, Gao G, Wang M, Lu Y, Li L, Chen C, Chen Y, Song C, Yu F, Li Y, Liu Y, Luo Y, He H, Cheng C, Xu L, Zhang T, Sun L, Liu A, Xia W, Qin Y, Zhao Q, Wei H, Cai W, Chen Y, Zhang F, Wu H. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet Reg Health West Pac 2023; 36:100769. [PMID: 37547039 PMCID: PMC10398592 DOI: 10.1016/j.lanwpc.2023.100769] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 03/29/2023] [Indexed: 08/08/2023]
Abstract
Background Ainuovirine (ANV) is a new non-nucleoside reverse transcriptase inhibitor (NNRTI), which was initially synthesized in Korea and later further developed in both Korea and China. Methods A randomized, double-blind, double-dummy, positive parallel group, non-inferiority, phase 3 trial was conducted in 7 sites across China. Eligible HIV-1-positive antiretroviral therapy (ART)-naïve adults aged 18-65 years were randomly assigned in a 1:1 ratio to receive tenofovir disoproxil fumarate and lamivudine (TDF+3TC) in combination with either ANV (ANV group) or efavirenz (EFV group) for up to 48 weeks. Subsequently, participants in both groups received one of the two drug combinations according to their choice until week 96 in an observational study under an open-label setting. The primary endpoint was the proportion of participants achieving HIV RNA <50 copies/mL at week 48, with non-inferiority pre-specified at a margin of 10%. The secondary efficacy endpoints were logarithmic changes in HIV RNA, percentage of participants with HIV RNA levels ≤400 copies/mL and changes in the CD4 T-cell count after 48 and 96 weeks of treatment, as well as the percentage of participants with HIV RNA levels <50 copies/mL at 96 weeks of treatment. Safety endpoints were the incidence of adverse events and laboratory abnormalities evaluated according to the Division of AIDS criteria. This study was registered with the Chinese Clinical Trial Registry (Registration number: ChiCTR1800019041). Findings Between November 27, 2018 and March 11, 2021, a total of 826 participants were screened, and 630 were finally enrolled and randomly assigned (1:1) to either ANV (n = 315) or EFV (n = 315) groups. The mean age was 30.6 ± 9.4 years and most participants were male (94.6%). At week 48, 274 (87.0%) of 315 participants in the ANV group and 288 (91.7%) of 314 in the EFV group achieved HIV-1 RNA <50 copies/mL and non-inferiority was established (difference: -4.7%, 95% CI: -9.6 to 0.1%). In the period, 293 participants continued to take the ANV regimen and 287 switched from the EFV to the ANV regimen. During the open-label period, 92.5% (271/293) of participants in the continued ANV group and 95.1% (273/287) in the ANV to EFV transfer group remained virologically suppressed (HIV-1 RNA <50 copies/mL) at week 96 (p = 0.189). The incidence of NNRTI treatment-related adverse events (TEAEs) at week 48 was 67.6% in 315 participants in the ANV group, which was significantly lower than in 91.4% of 314 participants in the EFV group (p < 0.001). The most common TEAEs (weeks 0-48) were dizziness (10.5%) and dyslipidemia (22.2%) in the ANV group vs. 51.0% and 34.4% in the EFV group, respectively, followed by transaminase elevation (9.2% vs. 29.0%), γ-glutamyl transferase elevation (8.3% vs. 19.1%), and rash (7.9% vs. 18.8%) (all p < 0.001). After switching from EFV to ANV, TEAEs in the former EFV participants were significantly reduced in the following observational period of 48-96 weeks. Interpretation The week 48 results indicated that the efficacy of ANV was non-inferior to EFV when combined with two NRTIs. The per-protocol risk difference at week 48 for the primary endpoint also supported non-inferiority. TEAEs in ANV treated participants were less frequent with regard to liver toxicity, dyslipidemia, neuropsychiatric symptoms and rash compared to the EFV group during the first 48 weeks of therapy. The effects were maintained during the 48-96 weeks of therapy. Funding Jiangsu Aidea Pharmaceutical Co., Ltd.
Collapse
Affiliation(s)
- Bin Su
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - Guiju Gao
- Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Min Wang
- Institute of HIV/AIDS, The First Hospital of Changsha, Changsha, Hunan, 410005, China
| | - Yanqiu Lu
- Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, 400036, China
| | - Linghua Li
- Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China
| | - Chen Chen
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003, China
| | - Yuanyuan Chen
- Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan, 450015, China
| | - Chuan Song
- Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Fengting Yu
- Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Ying Li
- Institute of HIV/AIDS, The First Hospital of Changsha, Changsha, Hunan, 410005, China
| | - Yixin Liu
- Institute of HIV/AIDS, The First Hospital of Changsha, Changsha, Hunan, 410005, China
| | - Yang Luo
- Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, 400036, China
| | - Haolan He
- Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China
| | - Cong Cheng
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003, China
| | - Lixia Xu
- Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan, 450015, China
| | - Tong Zhang
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - Lijun Sun
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - An Liu
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - Wei Xia
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - Yuanyuan Qin
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
- Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, 400036, China
| | - Qingxia Zhao
- Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan, 450015, China
| | - Hongxia Wei
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003, China
| | - Weiping Cai
- Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China
| | - Yaokai Chen
- Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, 400036, China
| | - Fujie Zhang
- Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
| | - Hao Wu
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| |
Collapse
|
8
|
Ren W, Gao G, Fang Y, Wang T, Zhu C, Xiao J, Wang F, Ni L, Yang D. WITHDRAWN: Long-term Survival Analysis of 30 Maintenance Hemodialysis Patients with HIV Infection in a Single-center in China. Curr HIV Res 2023; 21:CHR-EPUB-131342. [PMID: 37132139 DOI: 10.2174/1570162x21666230428163809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 03/06/2023] [Accepted: 03/06/2023] [Indexed: 05/04/2023]
Abstract
The article has been withdrawn at the request of the author of the journal Current HIV Research (CHIVR). Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication
Collapse
Affiliation(s)
- Wenwen Ren
- Department of Nephrology, Beijing Ditan Hospital, Capital Medical Universi-ty, NO.8 Jingshun East Street,Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Yajuan Fang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Tongtong Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Chunyu Zhu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Fang Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Liang Ni
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, NO.8 Jingshun East Street, Beijing, China
| |
Collapse
|
9
|
Lei YN, Li XY, Gao G, Wang WY, Liang ZY, Wang YS. Could immune-related hepatitis rapidly progress to immune-related cirrhosis? Eur Rev Med Pharmacol Sci 2023; 27:1436-1442. [PMID: 36876683 DOI: 10.26355/eurrev_202302_31383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
Abstract
BACKGROUND Immune-related hepatitis is one of the prevalent adverse events associated with immunotherapy, especially immune checkpoint inhibitors (ICIs). For patients without a history of liver disease, autoimmune disease, or alcohol consumption, it is not clear whether immune-related hepatitis could rapid progress to immune-related cirrhosis. CASE REPORT We report the case of a 54-year-old female with stage IIIB primary pulmonary lymphoepithelioma-like carcinoma (PLELC) diagnosed with immune-related hepatitis. After 15 months, a liver biopsy demonstrated the rapid progression of liver cirrhosis although systematic corticosteroid administration. CONCLUSIONS Long-term immune activation caused by ICIs may exacerbate the process of cirrhosis. Great attention should be paid to the rapid progression to liver cirrhosis of immune-related hepatitis in the clinic.
Collapse
Affiliation(s)
- Y-N Lei
- Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
| | | | | | | | | | | |
Collapse
|
10
|
Martinez-Navio J, Fuchs S, Mendes D, Muniz CR, Rakasz E, Gao G, Lifson J, Desrosiers R. OP 6.6 – 00134 Viral Suppression in SHIV-infected Rhesus Macaques following AAVmediated Delivery of Closer-to-germline Monoclonal Antibodies. J Virus Erad 2022. [DOI: 10.1016/j.jve.2022.100251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
11
|
Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, Gao G. Addressing Algorithmic Bias and the Perpetuation of Health Inequities: An AI Bias Aware Framework. Health Policy and Technology 2022. [DOI: 10.1016/j.hlpt.2022.100702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
12
|
Gao G, Chen P, Zhou C, Zhao X, Zhang K, Wu R, Zhang C, Wang Y, Xie Y, Wang Q. Genome-wide association study for reproduction-related traits in Chinese domestic goose. Br Poult Sci 2022; 63:754-760. [PMID: 35775663 DOI: 10.1080/00071668.2022.2096402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
1. This study measured six reproduction traits in a Sichuan white goose population (209 individuals), including fertility, qualified egg rate, plasma concentrations of progesterone (P), follicle-stimulating hormone (FSH), prolactin (PRL) and oestrogen (E2).2. Whole-genome resequencing data from the same goose population (209 individuals) were used in a genome-wide association study (GWAS) utilising a mixed linear model to investigate the genes and genetic markers associated with reproduction traits. The frequency of the selected SNPs and haplotypes were determined using the Matrix-Assisted Laser Desorption Ionisation Time-Of-Flight Mass Spectrometry (MALDI-TOF MS) method.3. In total, 42 SNPs significantly associated with these traits were identified. A haplotype block was constructed based on five SNPs that were significantly associated with qualified egg rate, with individuals having the haplotype CCTTAAGGAA having the lowest qualified egg rate.4. In conclusion, these results provided potential markers for marker-assisted selection to improve goose reproductive performance and a basis for elucidating the genetics of goose reproduction.
Collapse
Affiliation(s)
- G Gao
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Institute of Animal Genetics and Breeding, College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - P Chen
- Animal Husbandry and Veterinary Station, Sucheng District Suqian, Jiangsu, P. R. China
| | - C Zhou
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - X Zhao
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - K Zhang
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - R Wu
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - C Zhang
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - Y Wang
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - Y Xie
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| | - Q Wang
- Department of Poultry Science, Chongqing Academy of Animal Science, Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement, Chongqing, P. R. China
| |
Collapse
|
13
|
Gao G, Zhu C, Liu Y, Yang S, Xiao J, Zhao H, Yang D, Liang H, Wang F, Wu L, Zhang F, Ni L. Performance of Xpert MTB/RIF for Diagnosis of Tuberculosis in HIV-Infected People in China: A Retrospective, Single-Center Study. Med Sci Monit 2022; 28:e937264. [PMID: 36196026 PMCID: PMC9549759 DOI: 10.12659/msm.937264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background There are few studies of GeneXpert MTB/RIF (hereafter referred to as Xpert) detection technology in HIV-infected people in China. Therefore, this study aimed to evaluate the value of Xpert in HIV/TB co-infected patients and to provide reference and guidance for the diagnosis of TB in HIV-infected populations. Material/Methods This study reviewed medical records of human immunodeficiency virus (HIV) patients hospitalized at the Infection Center of Beijing Ditan Hospital affiliated to Capital Medical University from January 2018 to May 2020, and patients diagnosed with pulmonary and extrapulmonary tuberculosis were screened as study subjects. Sensitivity and specificity of Xpert were analyzed using ROC curves. Results Of the 413 HIV patients, 177 patients met the entry criteria, of which the diagnosis was active pulmonary tuberculosis (PTB): 145 and extrapulmonary tuberculosis (EPTB): 32. The sensitivity of Xpert for PTB and EPTB was 82.0% and 100%, higher than that of acid-fast bacilli (AFB) (61.0% and 58.3%), and slightly lower than that of T-SPOT.TB (91.0% and 100%); the specificity was 83.7% and 93.5%, higher than that of AFB (72.6%, 87.1%) and T-SPOT.TB (16.6%, 21.2%). The sensitivity of Xpert was 100% in bronchoalveolar lavage fluid (BALF) and 80.0% in sputum; in patients with CD4+ <200 cells/mm3, the sensitivity of Xpert was 90.0% and specificity was 84.8%, higher than that of AFB (60.0%, 75.5%) and T-SPOT.TB (90.0%, 21.5%). Conclusions Xpert has a high accuracy in HIV/TB co-infected patients, and Xpert still shows a high sensitivity and specificity even in HIV patients with CD4+ <200 cells/mm3. Xpert is recommended for the diagnosis of tuberculosis in HIV-infected patients.
Collapse
Affiliation(s)
- Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital Capital Medical University, Beijing, China (mainland)
| | - Chunyu Zhu
- Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Yingchu Liu
- School Of General Practice And Continung Education, Capital Medical University, Beijing, China (mainland)
| | - Siyuan Yang
- Laboratory of Infectious Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Hongyuan Liang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Fang Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Liang Wu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Fujie Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Liang Ni
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| |
Collapse
|
14
|
Wang J, Cheng Y, Wu Y, Cao F, Liu Q, Gao G. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
15
|
Zhou J, Bao M, Gao G, Cai Y, Wu L, Lei L, Zhao J, Ji X, Huang Y, Su C. EP08.01-107 The Increase of Blood Intratumor Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
16
|
Gao G, Jiang T, Zhou F, Wu F, Li W, Xiong A, Chen X, Ren S, Su C, Hu T, Li Q, Zhu C, Zhou C. EP16.01-005 Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Gao G, Cheng L, Zhao C, Li X, Yao C, Li F, You D, Zhou C. EP08.01-035 Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
18
|
Cho B, Lee SH, Han JY, Cho E, Lee JS, Lee K, Curtin J, Gao G, Xie J, Schnepp R, Bauml J, Knoblauch R, Thayu M, Kim DW. P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
19
|
Duan Y, Zhao H, Tang W, Chen M, Liu X, Yang D, Gao G, Xiao J, Han N, Liang H, Wu L, Ni L, Wang F, Song Y, Xie X, Zhang F. Longitudinal analysis of new-onset non-AIDS-defining diseases among people living with HIV: A real-world observational study. HIV Med 2022; 23 Suppl 1:32-41. [PMID: 35293109 DOI: 10.1111/hiv.13247] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2022] [Indexed: 01/01/2023]
Abstract
OBJECTIVES We aimed to analyze the incidence rates of new-onset diabetes, hypertriglyceridemia, hypercholesterolemia, liver injury, and renal injury during antiretroviral therapy (ART) among people living with HIV (PLWH) and determine the associated risk factors. METHODS This study included PLWH enrolled from Beijing Ditan Hospital from November 11, 2004, to December 29, 2018. The incidence rates of new-onset diabetes, hypertriglyceridemia, hypercholesterolemia, liver injury, and renal injury were calculated and stratified based on ART regimen, CD4 count, and HIV-RNA. Risk factors were determined using Cox regression analysis. RESULTS Overall, 6747 participants were included. Moreover, 4.5%, 43.3%, 25.4%, 11.2%, and 6.2% of patients developed new-onset diabetes, hypertriglyceridemia, hypercholesterolemia, liver injury, and renal injury, respectively, with incidence rates of 1.7, 26.9, 10.2, 3.9, and 5.5 per 100 person-years, respectively. Longitudinally, the incidence rates and percentages of these outcomes were highest in the first year of ART. The percentage of dyslipidemia was significantly higher in protease inhibitor (PI)-based regimen than in non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. However, the percentage of liver injury was significantly higher in NNRTI-based regimen than in PI-based regimen. In multivariate Cox regression analysis, low CD4 count (<200 cells/µL, adjusted hazard ratio [aHR] = 1.34, 95% confidence interval [CI] 1.15-1.57) and high HIV-RNA (>105 copies/mL, aHR = 1.26, 95% CI 1.08-1.48) were risk factors for hypertriglyceridemia. CONCLUSIONS Clinical outcomes, including new-onset diabetes, dyslipidemia, and liver and renal injuries, are common in PLWH. Regular glucose, lipid, liver, and renal function monitoring is required during ART, especially in high-risk patients.
Collapse
Affiliation(s)
- Yujiao Duan
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Weiming Tang
- University of North Carolina Project-China, Guangzhou, China
| | - Meiling Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Xuan Liu
- North Carolina State University, Raleigh, North Carolina, USA
| | - Di Yang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Jiang Xiao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Ning Han
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Hongyuan Liang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Liang Wu
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Liang Ni
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Fang Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Yangzi Song
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Xiaohui Xie
- Peking University Ditan Teaching Hospital, Beijing, China
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| |
Collapse
|
20
|
Li J, Du P, Yang L, Zhang J, Song C, Chen D, Song Y, Ding N, Hua M, Han K, Song R, Xie W, Chen Z, Wang X, Liu J, Xu Y, Gao G, Wang Q, Pu L, Di L, Li J, Yue J, Han J, Zhao X, Yan Y, Yu F, Wu AR, Zhang F, Gao YQ, Huang Y, Wang J, Zeng H, Chen C. Two-step fitness selection for intra-host variations in SARS-CoV-2. Cell Rep 2022; 38:110205. [PMID: 34982968 PMCID: PMC8674508 DOI: 10.1016/j.celrep.2021.110205] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 10/10/2021] [Accepted: 12/13/2021] [Indexed: 12/30/2022] Open
Abstract
Spontaneous mutations introduce uncertainty into coronavirus disease 2019 (COVID-19) control procedures and vaccine development. Here, we perform a spatiotemporal analysis on intra-host single-nucleotide variants (iSNVs) in 402 clinical samples from 170 affected individuals, which reveals an increase in genetic diversity over time after symptom onset in individuals. Nonsynonymous mutations are overrepresented in the pool of iSNVs but underrepresented at the single-nucleotide polymorphism (SNP) level, suggesting a two-step fitness selection process: a large number of nonsynonymous substitutions are generated in the host (positive selection), and these substitutions tend to be unfixed as SNPs in the population (negative selection). Dynamic iSNV changes in subpopulations with different gender, age, illness severity, and viral shedding time displayed a varied fitness selection process among populations. Our study highlights that iSNVs provide a mutational pool shaping the rapid global evolution of the virus.
Collapse
Affiliation(s)
- Jiarui Li
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Pengcheng Du
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Lijiang Yang
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics, Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China
| | - Ju Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Chuan Song
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Danying Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Yangzi Song
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Nan Ding
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Mingxi Hua
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Kai Han
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Rui Song
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Wen Xie
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Zhihai Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Xianbo Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Jingyuan Liu
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Yanli Xu
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Qi Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Lin Pu
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Lin Di
- Beijing Advanced Innovation Center for Genomics, Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China; Institute for Cell Analysis, Shenzhen Bay Laboratory, Shenzhen 518055, China
| | - Jie Li
- School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing 100084, China
| | - Jinglin Yue
- Peking University Ditan Teaching Hospital, Beijing 100015, China
| | - Junyan Han
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Xuesen Zhao
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Yonghong Yan
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100015, P. R. China
| | - Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China
| | - Angela R Wu
- Division of Life Science, Hong Kong University of Science and Technology, Hong Kong SAR, P.R. China; Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong SAR, P.R. China
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P. R. China.
| | - Yi Qin Gao
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics, Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518055, China.
| | - Yanyi Huang
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Beijing Advanced Innovation Center for Genomics, Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, China; School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China; Institute for Cell Analysis, Shenzhen Bay Laboratory, Shenzhen 518055, China; Chinese Institute for Brain Research, Beijing 102206, China.
| | - Jianbin Wang
- School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing 100084, China; Chinese Institute for Brain Research, Beijing 102206, China.
| | - Hui Zeng
- Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
| | - Chen Chen
- Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
| |
Collapse
|
21
|
Wang F, Xiang P, Zhao H, Gao G, Yang D, Xiao J, Han N, Wu L, Liang H, Ni L, Duan Y, Xu Q, Chen M, Zhang F. A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China. Sci Rep 2021; 11:24353. [PMID: 34934097 PMCID: PMC8692320 DOI: 10.1038/s41598-021-03672-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 12/06/2021] [Indexed: 01/15/2023] Open
Abstract
HIV-associated malignancies are responsible for morbidity and mortality increasingly in the era of potent antiretroviral therapy. This study aimed to investigate the distribution of HIV-associated malignancies among inpatients, the immunodeficiency and the effect of antiretroviral therapy (ART) on spectrum of HIV-associated malignancies. A total of 438 cases were enrolled from 2007 to 2020 in Beijing Ditan Hospital. Demographic, clinical and laboratory data, managements, and outcomes were collected and analyzed retrospectively. Of 438 cases, 433 were assigned to non-AIDS-defining cancers (NADCs) (n = 200, 45.7%) and AIDS-defining cancers (ADCs) (n = 233, 53.2%), 5 (1.1%) with lymphoma were not specified further. No significant change was observed in the proportion of NADCs and ADCs as time goes on. Of NADCs, lung cancer (n = 38, 19%) was the most common type, followed by thyroid cancer (n = 17, 8.5%). Patients with ADCs had lower CD4 counts(104.5/μL vs. 314/μL), less suppression of HIVRNA(OR 0.23, 95%CI 0.16–0.35) compared to those with NADCs. ART did not affect spectrum of NADCs, but affect that of ADCs (between patients with detectable and undetectable HIVRNA). ADCs remain frequent in China, and NADCs play an important role in morbidity and mortality of HIV positive population.
Collapse
Affiliation(s)
- Fang Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Pan Xiang
- Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Ning Han
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Wu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongyuan Liang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Ni
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yujiao Duan
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Qiuhua Xu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Meiling Chen
- The Medical Statistic Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Fujie Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| |
Collapse
|
22
|
Zhou C, Gao G, Wu L, Wang Z, Chen G, Huang D, Yang Z, Zhou C, Liu L, Li H. 150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
23
|
Li Q, Chen M, Zhao H, Yu F, Yan L, Xiao J, Gao G, Yang D, Zhang F. Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China. Infect Drug Resist 2021; 14:4529-4537. [PMID: 34754201 PMCID: PMC8572020 DOI: 10.2147/idr.s332924] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 10/09/2021] [Indexed: 12/11/2022] Open
Abstract
Background Whether intermittent low-level viremia (iLLV/blip) or persistent low-level viremia (pLLV) increases the risk of virologic failure (VF) in HIV-1 patients is controversial. The objective of this study was to investigate the incidence of blip/pLLV and the association between blip/pLLV and VF in a Chinese antiretroviral therapy cohort. Methods HIV-1 patients who underwent antiretroviral therapy (ART) from 2005 to 2018 and had at least two viral load (VL) measurements after a minimum of 6 months ART treatment were included. VF was defined as one or more VL measurements of ≥1000 copies/mL. Blip was described as an isolated VL measurement between 50 and 999 copies/mL, and pLLV was defined as two or more consecutive VL measurements between 50 and 999 copies/mL. Blip and pLLV were categorized separately into three groups: 50–200, 201–400 and 401–999 copies/mL. The Cox proportional hazard model was used to explore the association between blip/pLLV and VF. Results In total, 8098 participants were enrolled in this long-term cohort study. A 94.3% of the participants were male and among which 77.3% were infected through homosexual transmission. Blip occurred in 4.0% (325/8098) of the patients with an incidence of 0.73 per 100 person-years (/100 PYS) of follow-up (95% CI: 0.71–0.76), whereas pLLV occurred in 1.3% of the patients (102/8098) with an incidence of 0.23/100 PYS of follow-up (95% CI: 0.21–0.25). All the three categories of pLLV were associated with VF: pLLV 50–200 [aHR: 3.82 (1.95–7.47)], pLLV 201–400 [aHR: 5.36 (2.35–12.22)] and pLLV 401–999 [aHR: 13.51 (8.28–22.02)]. However, blip is not significantly associated with VF in any category. Conclusion Our study suggested that patients with pLLV had an increased risk of subsequent VF. Therefore, if pLLV occurs in patients, monitoring and corresponding measurements must be strengthened to avoid the subsequent VF.
Collapse
Affiliation(s)
- Qun Li
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Meiling Chen
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China.,The Medical Statistic Department, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Hongxin Zhao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Fengting Yu
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China.,Laboratory of Infectious Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Liting Yan
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Jiang Xiao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Guiju Gao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Di Yang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| | - Fujie Zhang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, People's Republic of China
| |
Collapse
|
24
|
Zhang L, Wang Y, Zhang Z, Liang H, Wu L, Ni L, Gao G, Yang D, Zhao H, Xiao J. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord 2021; 21:438. [PMID: 34525967 PMCID: PMC8442433 DOI: 10.1186/s12872-021-02245-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 09/02/2021] [Indexed: 11/21/2022] Open
Abstract
Background The risk factors of in-stent restenosis (ISR) among coronary artery disease (CAD) patients with syphilis after percutaneous coronary intervention (PCI) are not fully understood. Therefore, this study aimed to elucidate not only the risk factors of ISR among CAD patients with syphilis after performing PCI, but also the population attributable risk percentage (PAR%), which is used to quantify the proportion of ISR that could be eliminated if particular risk factors are not present. Methods Evaluation of the prevalence, risk factors, and their PAR% for ISR among CAD patients with syphilis undergoing PCI was conducted retrospectively at Beijing Ditan Hospital. CAD patients with syphilis underwent PCI from August 2010 to August 2019 and received a diagnosis, coronary angiography, PCI, and periodical follow-up. The clinical, laboratory, and imaging data were reviewed and summarised anonymously from electronic medical records. The chi-square or Fisher exact test was used in data analysis. Results Among 114 CAD patients with syphilis undergoing PCI, ISR occurred in 18 patients (15.78%). The multivariate Cox regression model indicated that average stent length ≥ 35 mm (adjusted hazard ratio [HR] = 4.47, 95% confidence interval [CI] = 1.30–15.44, p = 0.018) and titres of the toluidine red unheated serum test (TRUST) > 1:16 (adjusted HR = 3.72, 95% CI = 1.22–11.36, p = 0.021) were associated with an increased risk of ISR, while successful antisyphilitic treatment (adjusted HR = 0.12, 95% CI = 0.02–0.95, p = 0.045) was protective predictor of ISR among these patients. The PAR% values of particular risk factors associated with ISR including average stent length ≥ 35 mm, titres of TRUST > 1:16, and successful antisyphilitic treatment were 12.2%, 24.0%, and -39.6%, respectively, among these patients. Conclusions Preventing the occurrence of ISR among CAD patients with syphilis undergoing PCI requires clinical intervention. Our results indicated that carefully evaluating the length of the vessel lesion to determine whether the stent length is < 35 mm, prioritising the clinical intervention for titres of TRUST > 1:16, and providing successful antisyphilitic treatment could reduce the risk of ISR occurrence.
Collapse
Affiliation(s)
- Ling Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yu Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Zhe Zhang
- Beijing Fuxing Hospital, Capital Medical University, XiCheng District, Beijing, China
| | - Hongyuan Liang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Wu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Ni
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| |
Collapse
|
25
|
Zhao N, Zeng Z, Liang H, Wang F, Yang D, Xiao J, Chen M, Zhao H, Zhang F, Gao G. Estimation of renal function by three CKD-EPI equations in Chinese HIV/AIDS patients: A STROBE-compliant article. Medicine (Baltimore) 2021; 100:e26003. [PMID: 34087846 PMCID: PMC8183803 DOI: 10.1097/md.0000000000026003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 05/01/2021] [Indexed: 01/04/2023] Open
Abstract
Assessing renal function accurately is important for human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) patients. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recommended three equations to calculate estimated glomerular filtration rate (eGFR). There is evidence that eGFR based on the combination of serum creatinine and cystatin C is the most accurate of the three equations. But there is limited data on the comparison of three CKD-EPI equations in Chinese HIV/AIDS patients. The aim of our study was to compare the three CKD-EPI equations in Chinese HIV/AIDS population and assess renal function.Cross-sectional, single center, prospective study.One hundred seventy two Chinese adult HIV/AIDS patients were enrolled, including 145 (84.3%) males and 27 (15.7%) females. Mean age was 40(±12) years old. Overall mean eGFR based on serum creatinine, cystatin C and the combination of the 2 markers was 112.6(±19.0) mL/min/1.73 m2, 92.0(±24.2)mL/min/1.73 m2, and 101.7(±21.8)mL/min/1.73 m2, respectively (P = .000). The eGFR calculated by serum creatinine alone is higher than eGFR calculated by combination of serum creatinine and cystatin C, and eGFR calculated by cystatin C individual is lower than eGFR calculated by combination of the 2 markers.Of the 3 CKD-EPI equations, the CKD-EPIscr-cys equation may have the most accuracy in evaluating renal function in Chinese HIV/AIDS patients while the CKD-EPIscr equation may overestimate renal function and the CKD-EPIcys equation may underestimate renal function.
Collapse
Affiliation(s)
| | | | | | - Fang Wang
- Clinical and Research Center of Infectious Diseases
| | - Di Yang
- Clinical and Research Center of Infectious Diseases
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases
| | - Meiling Chen
- Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, China
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases
| | - Fujie Zhang
- Clinical and Research Center of Infectious Diseases
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases
| |
Collapse
|
26
|
Wang L, Jin YP, Gao G, Wu DY, Zhou XJ, Liu YY, Xia QX. [Clinicopathological features and molecular genetics of Burkitt-like lymphoma with 11q aberration]. Zhonghua Bing Li Xue Za Zhi 2021; 50:655-657. [PMID: 34078056 DOI: 10.3760/cma.j.cn112151-20201228-00980] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- L Wang
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Y P Jin
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - G Gao
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - D Y Wu
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - X J Zhou
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Y Y Liu
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Q X Xia
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| |
Collapse
|
27
|
Song Y, Chen C, Wang Y, Zhang J, Chen M, Gao G, Wang S, Yang D, Song R, Wang L, Xie W, Yu F, Yan L, Wang Y, Zeng H, Zhang F. Early and consecutive RT-PCR tests with both oropharyngeal swabs and sputum could improve testing yield for patients with COVID-19: An observation cohort study in China. Int J Infect Dis 2021; 107:242-246. [PMID: 33930545 PMCID: PMC8079261 DOI: 10.1016/j.ijid.2021.04.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 04/20/2021] [Accepted: 04/23/2021] [Indexed: 11/30/2022] Open
Abstract
Objective The real-time polymerase chain reaction (RT-PCR) test is recommended for the diagnosis of COVID-19 and provides a powerful tool to identify new infections and facilitate contact tracing. In fact, as the prevalence of COVID-19 decreases, this RT-PCR testing remains as the main preventive measure to avoid rebound. However, inconsistent results can lead to misdiagnoses in the clinic. These inconsistencies are due to the variability in (1) the collection times of biological samples post infection, and (2) sampling procedures. Methods We applied the Kaplan–Meier method and multivariate logistic regression on RT-PCR results from 258 confirmed patients with COVID-19 to evaluate the factors associated with negative conversion. We also estimated the proportion (%) of negative conversion among patients who had tested twice or more, and compared the proportions arising from oropharyngeal swabs, sputum, and combined double testing, respectively. Main results The proportion of negative conversion was 6.7% on day 4, 16.4% on day 7, 41.0% at 2 weeks, and 61.0% at 3 weeks post-admission. We also found that 34.1% and 60.3% of subjects had at least one negative RT-PCR result on days 7 and 14 after the onset of symptoms, respectively. The proportion of negative conversions following sputum testing was higher than that from oropharyngeal swabs in the early stages but this declined after the onset of symptoms. Conclusion In the absence of effective treatments or vaccines, efficient testing strategies are critical if we are to control the COVID-19 epidemic. According to this study, early, consecutive and combined double testing, will be the key to identify infected patients, particularly for asymptomatic and mild symptomatic cases. These strategies will minimize misdiagnosis and the ineffective isolation of infected patients.
Collapse
Affiliation(s)
- Yangzi Song
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100102, China.
| | - Chen Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100102, China.
| | - Yu Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Ju Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100102, China.
| | - Meiling Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Sa Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Di Yang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Rui Song
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Linghang Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Wen Xie
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Liting Yan
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Yajie Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.
| | - Hui Zeng
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100102, China.
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China; Beijing Key Laboratory of Emerging Infectious Diseases, Beijing 100102, China.
| |
Collapse
|
28
|
Han R, Jia Y, Li X, Zhao C, Zhao S, Liu S, Liu Y, Qiao M, Li J, Gao G, Su C, Ren S, Zhou C. P76.07 Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Wang Y, Liang H, Zhang L, Zhang Z, Wu L, Ni L, Gao G, Yang D, Zhao H, Xiao J. The burden of serious non-AIDS-defining events among admitted cART-naive AIDS patients in China: An observational cohort study. PLoS One 2020; 15:e0243773. [PMID: 33351812 PMCID: PMC7755215 DOI: 10.1371/journal.pone.0243773] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 11/29/2020] [Indexed: 12/17/2022] Open
Abstract
The objective of this study was to elucidate the burden, risk factors, and prognosis of serious non-AIDS-defining events among admitted cART-naive AIDS patients in China. The evaluation of the burden, risk factors and prognosis of serious NADEs was carried out among 1309 cART-naive AIDS patients (median age: 38.2 years, range: 18–78 years) admitted in Beijing Ditan Hospital between January 2009 and December 2018. Among 1309 patients, 143 patients (10.9%) had at least one serious NADEs, including 49 (3.8%) with cerebrovascular diseases, 37 (2.8%) with non-AIDS-defining cancers, 28 (2.1%) with chronic kidney diseases, 26 (2.0%) with cardiovascular diseases, and 18 (1.4%) with liver cirrhosis. Serious NADEs distributed in different age and CD4 levels, especially with age ≥50 years and CD4 ≤350 cells/ul. Other traditional risk factors, including cigarette smoking (OR = 1.9, 95%CI = 1.3–2.8, p = 0.002), hypertension (OR = 2.5, 95%CI = 1.7–3.7, p<0.001), chronic HCV infection (OR = 2.8, 95%CI = 1.4–5.6, p = 0.004), and hypercholesterolemia (OR = 4.1, 95% CI = 1.2–14.1, p = 0.026), were also associated with serious NADEs. Seventeen cases (1.3%) with serious NADEs died among hospitalized cART-naive AIDS patients, and severe pneumonia (HR = 5.5, 95%CI = 1.9–15.9, p<0.001) and AIDS-defining cancers (HR = 3.8, 95%CI = 1.1–13.2, p = 0.038) were identified as risk factors associated with an increased hazard of mortality among these patients with serious NADEs. Serious NADEs also occurred in cART-naive AIDS patients in China with low prevalence. Our results reminded physicians that early screening of serious NADEs, timely intervention of their risk factors, management of severe AIDS-defining events, multi-disciplinary cooperation, and early initiation of cART were essential to reduce the burden of serious NADEs.
Collapse
Affiliation(s)
- Yu Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongyuan Liang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Ling Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Zhe Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Wu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liang Ni
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Di Yang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- * E-mail: (HZ); (JX)
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- * E-mail: (HZ); (JX)
| |
Collapse
|
30
|
Qian F, Gao G, Song Y, Xu Y, Wang A, Wang S, Hao Y, Chen M, Ma X, Zhao T, Guo X, Chen Z, Zhang F. Specific dynamic variations in the peripheral blood lymphocyte subsets in COVID-19 and severe influenza A patients: a retrospective observational study. BMC Infect Dis 2020; 20:910. [PMID: 33261583 PMCID: PMC7705851 DOI: 10.1186/s12879-020-05637-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 11/19/2020] [Indexed: 02/08/2023] Open
Abstract
Background Both COVID-19 and influenza A contribute to increased mortality among the elderly and those with existing comorbidities. Changes in the underlying immune mechanisms determine patient prognosis. This study aimed to analyze the role of lymphocyte subsets in the immunopathogenesisof COVID-19 and severe influenza A, and examined the clinical significance of their alterations in the prognosis and recovery duration. Methods By retrospectively reviewing of patients in four groups (healthy controls, severe influenza A, non-severe COVID-19 and severe COVID-19) who were admitted to Ditan hospital between 2018 to 2020, we performed flow cytometric analysis and compared the absolute counts of leukocytes, lymphocytes, and lymphocyte subsets of the patients at different time points (weeks 1–4). Results We reviewed the patients’ data of 94 healthy blood donors, 80 Non-severe-COVID-19, 19 Severe-COVID-19 and 37 severe influenza A. We found total lymphocytes (0.81 × 109/L vs 1.74 × 109/L, P = 0.001; 0.87 × 109/L vs 1.74 × 109/L, P < 0.0001, respectively) and lymphocyte subsets (T cells, CD4+ and CD8+ T cell subsets) of severe COVID-19 and severe influenza A patients to be significantly lower than those of healthy donors at early infection stages. Further, significant dynamic variations were observed at different time points (weeks 1–4). Conclusions Our study suggests the plausible role of lymphocyte subsets in disease progression, which in turn affects prognosis and recovery duration in patients with severe COVID-19 and influenza A. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-020-05637-9.
Collapse
Affiliation(s)
- Fang Qian
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Yangzi Song
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Yanli Xu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Aibin Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Sa Wang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Yiwei Hao
- Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Meiling Chen
- Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Xiaoyang Ma
- Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Tianwei Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China
| | - Xiaodi Guo
- Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Zhihai Chen
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China.
| | - Fujie Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, No.8, Jing shun Dong jie, Chaoyang, 100015, District Beijing, China.
| |
Collapse
|
31
|
Wu L, Xiao J, Song Y, Gao G, Zhao H. The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study. BMC Infect Dis 2020; 20:912. [PMID: 33261581 PMCID: PMC7709347 DOI: 10.1186/s12879-020-05661-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 11/24/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Despite the profound impact of antiretroviral therapy in the control of AIDS mortality, central nervous system opportunistic infections remains a significant burden in AIDS patients. This retrospective study aims to elucidate the clinical characteristics, outcome and risk factors of cryptococcal meningitis (CM) poor prognosis in AIDS patients from a tertiary hospital in China. METHODS Clinical data from 128 patients admitted in Beijing Ditan Hospital, Capital Medical University from November 2008 to November 2017 was collected. The cohort was stratified based on treatment outcome (effective 79%, and ineffective 21%), and Multivariate Logistic regression analysis used to identify risk factors of poor disease prognosis. RESULTS Age, incidence of cerebral infarction, the proportion of consciousness disorder, and fasting plasma glucose was higher in the ineffective treatment group than the effective treatment group. The duration of treatment in the induction period of the ineffective group was significantly shorter than that of the effective group. Multivariate Logistic regression analysis indicated that the occurrence of cerebral hernia and consciousness disorder were risk factors for the prognosis of AIDS patients with CM infection, while the duration of treatment in the induction period was a indicative of a better prognosis in AIDS with CM infection complications. Finally, shunt decompression therapy correlated with a better disease outcome. CONCLUSIONS This retrospective study exposes the main risk factors associated with worse disease prognosis in AIDS patients with CM infection complications.
Collapse
Affiliation(s)
- Liang Wu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- The National Clinical Key Department of Infectious Diseases, The Infectious Diseases Research Institute of Capital Medical University, The Infectious Diseases Center of Beijing Ditan Hospital, 8 Jingshundong Street, Chaoyang District, Beijing, 100015, China
| | - Jiang Xiao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- The National Clinical Key Department of Infectious Diseases, The Infectious Diseases Research Institute of Capital Medical University, The Infectious Diseases Center of Beijing Ditan Hospital, 8 Jingshundong Street, Chaoyang District, Beijing, 100015, China
| | - Yangzi Song
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- The National Clinical Key Department of Infectious Diseases, The Infectious Diseases Research Institute of Capital Medical University, The Infectious Diseases Center of Beijing Ditan Hospital, 8 Jingshundong Street, Chaoyang District, Beijing, 100015, China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- The National Clinical Key Department of Infectious Diseases, The Infectious Diseases Research Institute of Capital Medical University, The Infectious Diseases Center of Beijing Ditan Hospital, 8 Jingshundong Street, Chaoyang District, Beijing, 100015, China
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- The National Clinical Key Department of Infectious Diseases, The Infectious Diseases Research Institute of Capital Medical University, The Infectious Diseases Center of Beijing Ditan Hospital, 8 Jingshundong Street, Chaoyang District, Beijing, 100015, China.
| |
Collapse
|
32
|
Yang S, Wang F, Yang D, Wang L, Liu D, Xu D, Gao G, Wang L. Case Report of False Rifampin Resistance with Xpert® MTB/RIF from an HIV Infected Patient. Clin Lab 2020; 66. [PMID: 33180430 DOI: 10.7754/clin.lab.2020.200409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Tuberculosis is one of the main infectious diseases threatening human health, especially in HIV co-infected patients. Xpert® MTB/RIF assay amplifies the rpoB gene of MTB was recommended by the World Health Organization as the initial diagnostic test in cases of suspected infections with Mycobacterium tuberculosis (MTB) or HIV-coinfected TB. METHODS A 44-year-old male HIV-positive patient co-infected with MTB presented with low-grade fever for 3 months. Rifampicin (RIF) resistance was detected in the celiac pus but not in the pleural effusion using Xpert® MTB/RIF assay. The same samples were then sequenced by next-generation sequencing (NGS) and in-house PCR for rpoB gene. RESULTS The results of NGS and in-house PCR, however, were paradoxical in the same samples with low or no mutation sequences of RIF resistance. The patient's tuberculosis (TB) therapy was optimized based on first-line anti-TB drugs and antiretroviral treatment. The patient improved with this therapy. CONCLUSIONS Even with high specificity, false positive results remain possible and RIF resistance detection by Xpert must be considered for clinical interpretation.
Collapse
|
33
|
Du P, Ding N, Li J, Zhang F, Wang Q, Chen Z, Song C, Han K, Xie W, Liu J, Wang L, Wei L, Ma S, Hua M, Yu F, Wang L, Wang W, An K, Chen J, Liu H, Gao G, Wang S, Huang Y, Wu AR, Wang J, Liu D, Zeng H, Chen C. Genomic surveillance of COVID-19 cases in Beijing. Nat Commun 2020; 11:5503. [PMID: 33127911 PMCID: PMC7603498 DOI: 10.1038/s41467-020-19345-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 10/06/2020] [Indexed: 02/07/2023] Open
Abstract
The spread of SARS-CoV-2 in Beijing before May, 2020 resulted from transmission following both domestic and global importation of cases. Here we present genomic surveillance data on 102 imported cases, which account for 17.2% of the total cases in Beijing. Our data suggest that all of the cases in Beijing can be broadly classified into one of three groups: Wuhan exposure, local transmission and overseas imports. We classify all sequenced genomes into seven clusters based on representative high-frequency single nucleotide polymorphisms (SNPs). Genomic comparisons reveal higher genomic diversity in the imported group compared to both the Wuhan exposure and local transmission groups, indicating continuous genomic evolution during global transmission. The imported group show region-specific SNPs, while the intra-host single nucleotide variations present as random features, and show no significant differences among groups. Epidemiological data suggest that detection of cases at immigration with mandatory quarantine may be an effective way to prevent recurring outbreaks triggered by imported cases. Notably, we also identify a set of novel indels. Our data imply that SARS-CoV-2 genomes may have high mutational tolerance.
Collapse
Affiliation(s)
- Pengcheng Du
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Nan Ding
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Jiarui Li
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Qi Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Zhihai Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Chuan Song
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Kai Han
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Wen Xie
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Jingyuan Liu
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Linghang Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Lirong Wei
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Shanfang Ma
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Mingxi Hua
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China
| | - Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Lin Wang
- MGI, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China
| | - Wei Wang
- MGI, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China
| | - Kang An
- BGI-Genomics, BGI-Shenzhen, Shenzhen, 518083, People's Republic of China
| | - Jianjun Chen
- CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China
- National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China
| | - Haizhou Liu
- National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Sa Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China
| | - Yanyi Huang
- Biomedical Pioneering Innovation Center (BIOPIC), Beijing Advanced Innovation Center for Genomics (ICG), College of Chemistry and Molecular Engineering, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, People's Republic of China
| | - Angela R Wu
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, SAR, People's Republic of China
| | - Jianbin Wang
- School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology (ICSB), Chinese Institute for Brain Research (CIBR), Tsinghua University, Beijing, 100084, People's Republic of China.
| | - Di Liu
- CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China.
- National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, People's Republic of China.
- University of Chinese Academy of Sciences, Beijing, 101409, People's Republic of China.
| | - Hui Zeng
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China.
| | - Chen Chen
- Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, 100015, People's Republic of China.
| |
Collapse
|
34
|
Du P, Song C, Li R, Song Y, Li J, Ding N, Zhang J, Song R, Han J, Gao G, Yue J, Duan A, Huang Y, An J, Wang J, Zhang F, Chen C, Zeng H. Specific re-distribution of SARS-CoV-2 variants in the respiratory system and intestinal tract. Clin Infect Dis 2020; 73:e2814-e2817. [PMID: 33086379 PMCID: PMC7665415 DOI: 10.1093/cid/ciaa1617] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Indexed: 01/18/2023] Open
Abstract
Intra-host analysis of SARS-CoV-2 genomic sequences identified two viral haplotypes that comprised of three genetically linked mutations from the respiratory and intestinal tracts of a patient with COVID-19. Spatiotemporal data suggest that this patient initially had dual-infection of two SARS-CoV-2 variants, which subsequently re-distributed into the two systems.
Collapse
Affiliation(s)
- Pengcheng Du
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Chuan Song
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Rui Li
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Yangzi Song
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Jiarui Li
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Nan Ding
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Ju Zhang
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Rui Song
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China
| | - Junyan Han
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Guiju Gao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China
| | - Jinglin Yue
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Ang Duan
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Yanyi Huang
- Biomedical Pioneering Innovation Center (BIOPIC), Beijing Advanced Innovation Center for Genomics (ICG), College of Chemistry and Molecular Engineering, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, P. R. China
| | - Jing An
- Depart of Microbiology, School of Basic Medical Science, Capital Medical University, Beijing, P. R. China
| | - Jianbin Wang
- School of Life Sciences, Beijing Advanced Innovation Center for Structural Biology (ICSB), Chinese Institute for Brain Research (CIBR), Tsinghua University, Beijing, P. R. China
| | - Fujie Zhang
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China
| | - Chen Chen
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| | - Hui Zeng
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, P. R. China
| |
Collapse
|
35
|
Wang A, Gao G, Wang S, Chen M, Qian F, Tang W, Xu Y, Song R, Zhuang L, Ma X, Zhao T, Guo X, Li W, Wang X, Li B, Hu C, Chen Z, Zhang F. Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. Med Sci Monit 2020; 26:e925974. [PMID: 32973126 PMCID: PMC7523414 DOI: 10.12659/msm.925974] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background Coronavirus disease 2019 (COVID-19) is a new infectious disease, and acute respiratory syndrome (ARDS) plays an important role in the process of disease aggravation. The detailed clinical course and risk factors of ARDS have not been well described. Material/Methods We retrospectively investigated the demographic, clinical, and laboratory data of adult confirmed cases of COVID-19 in Beijing Ditan Hospital from Jan 20 to Feb 29, 2020 and compared the differences between ARDS cases and non-ARDS cases. Univariate and multivariate logistic regression methods were employed to explore the risk factors associated with ARDS. Results Of the 130 adult patients enrolled in this study, the median age was 46.5 (34–62) years and 76 (58.5%) were male. ARDS developed in 26 (20.0%) and 1 (0.8%) death occurred. Fever occurred in 114 patients, with a median highest temperature of 38.5 (38–39)°C and median fever duration of 8 (3–11) days. The median time from illness onset to ARDS was 10 (6–13) days, the median time to chest CT improvement was 17 (14–21) days, and median time to negative nucleic acid test result was 27 (17–33) days. Multivariate regression analysis showed increasing odds of ARDS associated with age older than 65 years (OR=4.75, 95% CL1.26–17.89, P=0.021), lymphocyte counts [0.5–1×109/L (OR=8.80, 95% CL 2.22–34.99, P=0.002); <0.5×109/L(OR=36.23, 95% CL 4.63–2083.48, P=0.001)], and temperature peak ≥39.1°C (OR=5.35, 95% CL 1.38–20.76, P=0.015). Conclusions ARDS tended to occur in the second week of the disease course. Potential risk factors for ARDS were older age (>65 years), lymphopenia (≤1.0×109/L), and temperature peak (≥39.1°C). These findings could help clinicians to predict which patients will have a poor prognosis at an early stage.
Collapse
Affiliation(s)
- Aibin Wang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Guiju Gao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Sa Wang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Meiling Chen
- Medical Record Statistics Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Fang Qian
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Weiming Tang
- University of North Carolina Project-China, Chapel Hill, NC, USA
| | - Yanli Xu
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Rui Song
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Liwei Zhuang
- Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Xiaoyang Ma
- Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Tianwei Zhao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Xiaodi Guo
- Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Wei Li
- Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Xudong Wang
- Surgical Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Baoliang Li
- Surgical Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Chun Hu
- Surgical Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Zhihai Chen
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| | - Fujie Zhang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland)
| |
Collapse
|
36
|
Sinito C, Corfdir P, Pfüller C, Gao G, Bartolomé J, Kölling S, Doblado AR, Jahn U, Lähnemann J, Auzelle T, Zettler JK, Flissikowski T, Koenraad P, Grahn HT, Geelhaar L, Fernández-Garrido S, Brandt O. Correction to Absence of Quantum-Confined Stark Effect in GaN Quantum Disks Embedded in (Al,Ga)N Nanowires Grown by Molecular Beam Epitaxy. Nano Lett 2020; 20:6930. [PMID: 32794760 DOI: 10.1021/acs.nanolett.0c02938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
|
37
|
Gao G, Wang Y, Ren S, Zhao J, Chen G, Chen J, Gu K, Guo R, Pan Y, Wang Q, Zhou C. 1267P Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
38
|
Zhang H, Chen M, Zhang Y, Wen J, Wang Y, Wang L, Guo J, Liu C, Li D, Wang Y, Bai J, Gao G, Wang S, Yang D, Yu F, Yan L, Wan G, Zhang F. The Yield and Consistency of the Detection of SARS-CoV-2 in Multiple Respiratory Specimens. Open Forum Infect Dis 2020; 7:ofaa379. [PMID: 33072810 PMCID: PMC7499703 DOI: 10.1093/ofid/ofaa379] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 08/24/2020] [Indexed: 12/15/2022] Open
Abstract
Background Few studies have compared the yield of reverse transcription polymerase chain reaction (RT-PCR) assays in nasopharyngeal swabs, oropharyngeal swabs, and sputum for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. Methods We conducted an observational study in Beijing Ditan Hospital, China. Specimens including nasopharyngeal swabs, oropharyngeal swabs, and sputum from confirmed coronavirus 2019 patients were collected for RT-PCR testing. Disease duration was calculated from the date of symptom onset to the date of specimen collection and divided into 3 groups: ≤14 days, 14–21 days, and >21 days. We compared positive rates across the 3 specimens collected. The kappa coefficient was used to evaluate the consistency of RT-PCR results between different specimens. Results A total of 291 specimens were collected and tested from 43 confirmed patients. Among specimens collected with a disease duration of ≤14 days, the positive rate was highest in sputum (79.2%); this rate was significantly higher than that in nasopharyngeal swabs (37.5%; P = .003) and oropharyngeal swabs (20.8%; P < .001). Similar findings were observed with the disease durations of 14–21 days and >21 days. The consistency of testing results between nasopharyngeal swabs and oropharyngeal swabs was low with the disease durations of ≤14 days and >21 days. The consistency between the sputum and oropharyngeal swabs and between the sputum and nasopharyngeal swabs was very low across all 3 disease durations, with statistical significance. Conclusions Compared with nasopharyngeal swabs and oropharyngeal swabs, sputum had the highest yield of SARS-CoV-2 detection. Nasopharyngeal swabs and oropharyngeal swabs had a similar yield. If sputum is not feasible, a nasopharyngeal swab can be recommended for the detection of SARS-CoV-2, and early testing is needed.
Collapse
Affiliation(s)
- Haixia Zhang
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Meiling Chen
- The Medical Statistic Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yanhua Zhang
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jing Wen
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Yajie Wang
- Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liming Wang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - Jinjin Guo
- Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Chen Liu
- Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Daijing Li
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Ying Wang
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jing Bai
- The Nursing Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Sa Wang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Di Yang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Fengting Yu
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - Liting Yan
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - Gang Wan
- The Medical Statistic Department, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Fujie Zhang
- Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| |
Collapse
|
39
|
Wu Q, Zhou Y, Wang Y, Zhang Y, Shen Y, Su Q, Gao G, Xu H, Zhou X, Liu B. Whole-genome sequencing reveals breed-differential CNVs between Tongcheng and Large White pigs. Anim Genet 2020; 51:940-944. [PMID: 32808316 DOI: 10.1111/age.12993] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/24/2020] [Indexed: 01/26/2023]
Abstract
Large phenotypic differences have been observed between Tongcheng and Large White pigs. However, little is known about their genetic basis. This study performed a genome-wide comparison of CNVs between Tongcheng and Large White pigs using genome sequencing data. By combining the advantages of three different strategies (read depth, paired-end mapping and split read), we detected in total 18 687 CNVs that covered approximately 3.5% of the pig genome length for Tongcheng and Large White pigs. We identified 1864 breed-stratified CNVs (top 10%) by performing VST statistics. Functional enrichment analyses for genes located in breed-stratified CNVs were found to be involved in pigmentation, behavior, immune system and reproductive processes, which coincide with phenotypic differences between the two breeds. Using a systematic analysis of the genome and transcriptome data, we further identified four novel breed-differential CNVs on the functional genes (disease-resistant, DCUN1D2 and SPARCL1; lipid metabolism, PLEKHA2 and SLCO1A2). Subsequent PCR validation confirmed their accurate breakpoint positions in 33 Tongcheng pigs and 33 Large White pigs. This study provides essential information on differential CNVs for further research on the genetic basis of phenotypic differences between Tongcheng and Large White pigs.
Collapse
Affiliation(s)
- Q Wu
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - Y Zhou
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - Y Wang
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - Y Zhang
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - Y Shen
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - Q Su
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - G Gao
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - H Xu
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China
| | - X Zhou
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China.,The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, 430070, China
| | - B Liu
- Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, Key Laboratory of Pig Genetics and Breeding of Ministry of Agriculture and College of Animal Science and Technology, Huazhong Agricultural University, Wuhan, 430070, China.,The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, 430070, China
| |
Collapse
|
40
|
Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis 2020; 71:793-798. [PMID: 32221523 PMCID: PMC7184442 DOI: 10.1093/cid/ciaa345] [Citation(s) in RCA: 458] [Impact Index Per Article: 114.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 03/27/2020] [Indexed: 12/11/2022] Open
Abstract
Background Coronavirus disease 2019 (COVID-19) has become a public health emergency. The widely used reverse transcription PCR (RT-PCR) method has limitations for clinical diagnosis and treatment. Methods A total of 323 samples from 76 COVID-19 confirmed patients were analyzed by droplet digital PCR (ddPCR) and RT-PCR based two target genes (ORF1ab and N). Nasal swabs, throat swabs, sputum, blood, and urine were collected. Clinical and imaging data were obtained for clinical staging. Results In 95 samples tested positive by both methods, the cycle threshold (Ct) of RT-PCR was highly correlated with the copy numbed of ddPCR (ORF1ab gene, R2 = 0.83; N gene, R2 = 0.87). 4 (4/161) negative and 41 (41/67) single-gene positive samples tested by RT-PCR were positive according to ddPCR with viral load ranging from 11.1 to 123.2 copies/test. Then the viral load of respiratory samples was compared and the average viral load in sputum (17429 ± 6920 copies/test) was found to be significantly higher than in throat swabs (2552 ± 1965 copies/test, p < 0.001) and nasal swabs (651 ± 501 copies/test, p < 0.001). Furthermore, the viral load in the early and progressive stages were significantly higher than that in the recovery stage (46800 ± 17272 vs 1252 ± 1027, p < 0.001) analyzed by sputum samples. Conclusions Quantitative monitoring of viral load in lower respiratory tract samples helps to evaluate disease progression, especially in cases of low viral load.
Collapse
Affiliation(s)
- Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Liting Yan
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Nan Wang
- Human Genetic Resource Center, National Research Institute for Health and Family Planning, Beijing, China.,Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing, China
| | - Siyuan Yang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Linghang Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Yunxia Tang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Sa Wang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Chengjie Ma
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Ruming Xie
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Fang Wang
- Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China
| | - Chianru Tan
- Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China
| | - Lingxiang Zhu
- Human Genetic Resource Center, National Research Institute for Health and Family Planning, Beijing, China
| | - Yong Guo
- Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| |
Collapse
|
41
|
Gao X, Yang D, Yuan Z, Zhang Y, Li H, Gao P, Liu X, Zhao W, Xiao T, Guan Y, Gao G, Duan X. Improving the early diagnosis of suspected patients with COVID-19: a retrospective study of 106 patients. J Infect Dev Ctries 2020; 14:547-553. [PMID: 32683343 DOI: 10.3855/jidc.12992] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 05/19/2020] [Indexed: 10/31/2022] Open
Abstract
INTRODUCTION An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China. This study aimed to analyze the clinical and epidemiologic characteristics of patients with COVID-19 to better differentiate the suspected patients in Beijing, China. METHODOLOGY This was a retrospective, single-center study. Clinical and epidemiologic data were collected from suspected patients with COVID-19 admitted to Beijing Ditan Hospital from January 29 to February 21, 2020. RESULTS One hundred and six patients (60 males and 46 females, median age 36 years) were enrolled. Thirty-six patients were ultimately laboratory confirmed. Fifty-three were excluded from the diagnosis of COVID-19. The remaining 17 patients were highly suspected, although their nucleic acid tests were repeatedly negative. The confirmed patients and highly suspected patients had a significantly higher proportion of epidemiologic history than the excluded patients (P < 0.001). There was no significant difference in clinical symptoms or the underlying diseases among the three groups. The confirmed patients had a higher frequency of lymphopenia and eosinopenia than the highly suspected and excluded patients. Chest computed tomography scans showed bilateral lung involvement, and ground-glass opacity was more likely observed in the confirmed patients. CONCLUSION The clinical features of the confirmed patients with COVID-19 were insufficient for early diagnosis of COVID-19. The epidemiologic history was of great significance in the early diagnosis of COVID-19. More sensitive diagnostic methods are needed to aid the differential diagnosis of suspected patients with COVID-19.
Collapse
Affiliation(s)
- Xuesong Gao
- Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Di Yang
- Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Zheng Yuan
- Department of Orthopedics, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Yijin Zhang
- Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Hongjie Li
- Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Ping Gao
- Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Xiaomin Liu
- Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Wenshan Zhao
- Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Te Xiao
- Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Yanlin Guan
- Division of Disease Control, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Guiju Gao
- Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| | - Xuefei Duan
- Department of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
| |
Collapse
|
42
|
Zhang T, Gao G, Chang F. miR-152 promotes spinal cord injury recovery via c-jun amino terminal kinase pathway. Eur Rev Med Pharmacol Sci 2020; 23:44-51. [PMID: 30657545 DOI: 10.26355/eurrev_201901_16746] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The aim of this research is to explore the possible role of miR-152 in spinal cord injury and its underlying mechanism. MATERIALS AND METHODS After a mouse model of spinal cord injury (SCI) was developed, Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was used to detect the expression of miR-152 and c-jun in the mouse. In addition, the expression levels of interleukin-1b (IL-1b), interleukin-18 (IL-18) and tumor necrosis factor-α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA). Subsequently, miR-152 was overexpressed and the levels of inflammation and c-jun after spinal cord injury were detected by Western blot. Furthermore, the grip strength of double forelimb, left forelimb or right forelimb of the mice was detected using a grip force test after miR-152 was overexpressed in the injured area of each group. RESULTS By constructing a mouse model of spinal cord injury, we found that the expression of miR-152 in the injured area decreased with time; meanwhile, the inflammatory relative genes including IL-1b, IL18, TNF-α, and c-jun were significantly increased. However, miR-152 overexpression significantly reduced the levels of inflammation genes as well as the expression of c-jun. Besides, the strength of the forelimbs in the spinal cord injury mice was restored. CONCLUSIONS MiR-152 could inhibit inflammatory responses and promote the recovery of the spinal cord injury through the c-jun N-terminal kinase pathway and it can be a target molecular for treating spinal cord injury.
Collapse
Affiliation(s)
- T Zhang
- Department of Orthopaedic Surgery, Affiliated Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, China.
| | | | | |
Collapse
|
43
|
Chen C, Gao G, Xu Y, Pu L, Wang Q, Wang L, Wang W, Song Y, Chen M, Wang L, Yu F, Yang S, Tang Y, Zhao L, Wang H, Wang Y, Zeng H, Zhang F. SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. Ann Intern Med 2020; 172:832-834. [PMID: 32227141 PMCID: PMC7133055 DOI: 10.7326/m20-0991] [Citation(s) in RCA: 161] [Impact Index Per Article: 40.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Chen Chen
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Guiju Gao
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Yanli Xu
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Lin Pu
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Qi Wang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Liming Wang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Wenling Wang
- NHC Key Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (W.W., L.Z., H.W.)
| | - Yangzi Song
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Meiling Chen
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Linghang Wang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Siyuan Yang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Yunxia Tang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Li Zhao
- NHC Key Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (W.W., L.Z., H.W.)
| | - Huijuan Wang
- NHC Key Laboratory, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (W.W., L.Z., H.W.)
| | - Yajie Wang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Hui Zeng
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China (C.C., G.G., Y.X., L.P., Q.W., L.W., Y.S., M.C., L.W., F.Y., S.Y., Y.T., Y.W., H.Z., F.Z.)
| |
Collapse
|
44
|
Gao G, Wang YZ, Zhang YP, Feng SE, Hou M, Xia QX. [Clinicopathological and molecular features of pulmonary enteric adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi 2020; 49:544-549. [PMID: 32486530 DOI: 10.3760/cma.j.cn112151-20191018-00583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinicopathological and molecular characteristics of pulmonary enteric adenocarcinoma (PEAC). Methods: The clinical and pathological data of 19 cases of PEAC in the Affiliated Cancer Hospital of Zhengzhou University were retrospectively collected from 2015 to 2019. Immunohistochemistry (IHC) was used to detect the relevant immunophenotypes, amplification refractory mutation system (ARMS) and fluorescence in situ hybridization (FISH) were used to detect the expression of EGFR, KRAS and ALK genes. The patients were followed up, and the relevant literature was reviewed and analyzed. Results: There were 19 cases, including 10 males and 9 females, with a mean age of 58 years (range 33-71 years). Microscopically, the tumors showed moderately to highly differentiated adenoid and/or papillary growth patterns. The tumor cells were highly columnar and sometimes showed pseudostratification. Inflammatory necrosis and scattered nuclear fragmentation were seen in some glandular lumens. IHC showed variable expression of CK7 (19/19), TTF1 (8/19), Napsin A (6/19), villin (17/19), CK20 (16/19) and CDX2 (10/19). Molecular testing showed KRAS mutation in nine cases (9/19), EGFR mutation in one case (1/19), and positive ALK split signal in one case (1/19). In the literature, the reported mutation rate of KRAS in PEAC was much higher than that of EGFR and ALK. All 19 cases underwent surgical resection and 11 cases were subjected to chemotherapy or radiotherapy. Conclusions: PEAC is a rare variant of invasive pulmonary adenocarcinoma, and has similar histological and cytological features to that of colorectal adenocarcinoma. However, detailed medical history, histologic heterogeneity, an IHC combination of CK7(+)/villin(+) and high KRAS mutation rate are the key points of diagnosis. The prognosis needs long-term follow-up and big data statistics.
Collapse
Affiliation(s)
- G Gao
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Y Z Wang
- Department of Pathology, Shangcheng County People's Hospital, Henan Province, Shangcheng 465350, China
| | - Y P Zhang
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - S E Feng
- Department of Pathology, Henan Provincial Hospital, Zhengzhou 451475, China
| | - M Hou
- Department of Pathology, Henan Provincial People's Hospital, Zhengzhou 450008, China
| | - Q X Xia
- Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| |
Collapse
|
45
|
Gao G, Zhang K, Zhao X, Wu R, Zhong H, Li J, Li C, Xie Y, Wang Q. Molecular cloning of the goose GnRH gene and identification of GnRH polymorphisms associated with laying traits. Br Poult Sci 2020; 61:502-507. [PMID: 32306753 DOI: 10.1080/00071668.2020.1758298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
1. Egg-laying traits are important economic characteristics in goose production (Anser cygnoides). The gene GnRH, which encodes gonadotropin-releasing hormone, is a strong candidate gene for egg-laying traits in avian species. 2. In this study, a 3520 bp genomic sequence and a 279 bp mRNA sequence for GnRH, which encoded 92 amino acids, were determined. The GnRH DNA sequence contains four exons and three introns, and the DNA and deduced amino acid sequences were highly conserved across mammals (human, macaque, cow, and sheep) and avians (chicken, fulmar and quail). 3. Using a direct sequencing method, 46 single nucleotide polymorphisms (SNPs) were identified in the GnRH genomic sequence that were shared between two Sichuan White goose populations (217 and 208 individuals). Furthermore, 44 haplotypes were constructed using a sliding window approach. Association analysis between the SNPs and haplotypes and egg-laying traits showed that 10 SNPs affected the first egg weight, average egg weight, egg number at 48 weeks and egg number at 64 weeks. 4. These results lay the foundation for further studies of the function of GnRH in geese and provide a theoretical basis for marker-assisted selection of egg-laying traits in the Sichuan white goose population.
Collapse
Affiliation(s)
- G Gao
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - K Zhang
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - X Zhao
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - R Wu
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China
| | - H Zhong
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - J Li
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - C Li
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - Y Xie
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| | - Q Wang
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, China.,Poultry Science Department, Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, China
| |
Collapse
|
46
|
Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2020; 30:447-455. [PMID: 30596880 DOI: 10.1093/annonc/mdy542] [Citation(s) in RCA: 133] [Impact Index Per Article: 33.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This study investigated the antitumor effect of an irreversible pan-HER receptor tyrosine kinase inhibitor, pyrotinib. PATIENTS AND METHODS Using patient-derived organoids and xenografts established from an HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma patient sample, we investigated the antitumor activity of pyrotinib. Preliminary safety and efficacy of pyrotinib in 15 HER2-mutant NSCLC patients in a phase II clinical trial are also presented. RESULTS Pyrotinib showed significant growth inhibition of organoids relative to afatinib in vitro (P = 0.0038). In the PDX model, pyrotinib showed a superior antitumor effect than afatinib (P = 0.0471) and T-DM1 (P = 0.0138). Mice treated with pyrotinib displayed significant tumor burden reduction (mean tumor volume, -52.2%). In contrast, afatinib (25.4%) and T-DM1 (10.9%) showed no obvious reduction. Moreover, pyrotinib showed a robust ability to inhibit pHER2, pERK and pAkt. In the phase II cohort of 15 patients with HER2-mutant NSCLC, pyrotinib 400 mg resulted in a objective response rate of 53.3% and a median progression-free survival of 6.4 months. CONCLUSION Pyrotinib showed activity against NSCLC with HER2 exon 20 mutations in both patient-derived organoids and a PDX model. In the clinical trial, pyrotinib showed promising efficacy. CLINICAL TRIAL REGISTRATION NCT02535507.
Collapse
Affiliation(s)
- Y Wang
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - T Jiang
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - Z Qin
- Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai
| | - J Jiang
- Department of Medical Affairs, Hengrui Pharmaceutical Company, Shanghai, China
| | - Q Wang
- Department of Medical Affairs, Hengrui Pharmaceutical Company, Shanghai, China
| | - S Yang
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - C Rivard
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - G Gao
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - T L Ng
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - M M Tu
- Department of Surgery (Urology), University of Colorado Anschutz Medical Campus, Aurora; University of Colorado Comprehensive Cancer Center, Aurora
| | - H Yu
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - H Ji
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai
| | - C Zhou
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
| | - S Ren
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai; Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora.
| | - J Zhang
- Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, USA
| | - P Bunn
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - R C Doebele
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - D R Camidge
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| | - F R Hirsch
- Departments of Medicine, Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora
| |
Collapse
|
47
|
Zhang K, Gao G, Zhao X, Li Q, Zhong H, Xie Y, Wang Q. The direct effects of gonadotropin-releasing hormone on proliferation of granulosa cells and development of follicles in goose. Br Poult Sci 2020; 61:242-250. [PMID: 32019334 DOI: 10.1080/00071668.2020.1724877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
1. The study objectives were to determine the direct effects of gonadotropin-releasing hormone (GnRH) on the proliferation of ovarian granulosa cells (GCs) and the development of follicles in geese (Anser cygnoides) by colorimetry and ethynyl-2'-deoxyuridine (EdU) cell proliferation assays, in which primary GCs were treated with different concentrations of GnRH agonist (alarelin acetate) and an antagonist (cetrorelix acetate). Differently expressed genes (DEGs) were identified by RNA-sequencing and validated by quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blotting. 2. The EdU assays showed that the proliferation of GCs was affected by the GnRH agonist and antagonist in a dose-dependent manner. The effect of treatment on cell proliferation was statistically significant at the concentrations of 10-5 mol/l alarelin and 1 mg/l cetrorelix acetate. A total of 134 DEGs (76 downregulated and 58 upregulated for alarelin treatment) and 226 DEGs (90 downregulated and 136 upregulated for cetrorelix) were identified by RNA-sequencing analysis, respectively. Enrichment analysis indicated that DEGs were enriched in the GO terms of cell-cell signalling and cell junctions. The pathways that regulate the development of follicles were identified, including the biological progress of cAMP accumulation, ovulation cycle and vasculature that are essential to follicular selection. 3. The results suggested that GnRH might directly regulate GC proliferation via autocrine or paracrine pathways related to cell junctions. In particular, it was confirmed that the mRNA and protein expression levels of the oestrogen receptor 2 (ESR2) gene, a negative transcription factor involved in follicular maturation and ovulation, were affected by GnRH agonist or antagonist in GCs. 4. In conclusion, GnRH might play an important role in follicular development by changing the expression of genes that participate in cAMP accumulation, ovulation cycle and cell junctions in ovarian GCs.
Collapse
Affiliation(s)
- K Zhang
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - G Gao
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - X Zhao
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - Q Li
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - H Zhong
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - Y Xie
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| | - Q Wang
- Poultry Science Department, Chongqing Academy of Animal Science , Chongqing, P. R. China.,Chongqing Engineering Research Center of Goose Genetic Improvement , Chongqing, P. R. China
| |
Collapse
|
48
|
Huang X, Xu L, Sun L, Gao G, Cai W, Liu Y, Ding H, Wei H, Ma P, Wang M, Liu S, Chen Y, Chen X, Zhao Q, Yu J, Song Y, Chen H, Wu H, Qin S, Li L. Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China. Front Pharmacol 2019; 10:1455. [PMID: 31920648 PMCID: PMC6917650 DOI: 10.3389/fphar.2019.01455] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Accepted: 11/13/2019] [Indexed: 11/13/2022] Open
Abstract
The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain unknown. Therefore, we conducted a large-scale, multicenter retrospective cohort study to evaluate the efficacy and safety of LPV/r-based ART among HIV-infected adults in China in whom first-line therapy failed. The data were obtained from a national database covering 17 clinics in China for six years of follow-up from 2009 to 2016. Failure of first-line treatment was determined according to a viral load at least 400 copies/ml at week 48, non-completers at week 48 for any reason, and those who switched ART before week 48 for any reason such as side effects. Treatment effectiveness was assessed by the rate of CD4+T cell recovery, defined as >500 cells/mm3, and the proportion of patients achieving viral suppression, defined as <400 or <50 copies/ml according to the methods used during treatment. Safety was assessed by rates of LPV/r-related adverse events (AEs), including lipid disorder, severe abnormal liver function, myelosuppression, and renal function. Between 2009 and 2016, 1196 participants (median, 36 years old; IQR, 30–43 years) were ultimately enrolled. All patients had been on LPV/r-based second-line ART treatment for more than one year after failure of any first-line ART regimen. Overall CD4+T cell counts increased from 138 cells/mm3 to 475 cells/mm3 and 37.2% of all participants reached CD4 recovery. Viral suppression rates dramatically increased at the end of the first year (<400 copies/ml, 88.8%; <50 copies/ml, 76.7%) and gradually increased during follow-up (<400 copies/ml, 95.8%; <50 copies/ml, 94.4%). The most frequently reported AEs were LPV/r-induced lipid disorders with no obvious increase on LDL-C at follow-up visits. This is the first real-world LPV/r-based second-line treatment study to cover such a large population in China. These results provide strong clinical evidence that LPV/r-based second-line ART is effective in increasing CD4+T cell counts and viral suppression rates with tolerable side effects in HIV-infected adults in China in whom first-line treatment had failed.
Collapse
Affiliation(s)
- Xiaojie Huang
- Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China
| | - Liumei Xu
- Department of Clinical AIDS Research, the Third People's Hospital of Shenzhen, Shenzhen, China
| | - Lijun Sun
- Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China
| | - Guiju Gao
- Clinical and Research Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Weiping Cai
- InInfectious Diseases Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Yanfen Liu
- Center for Infectious Diseases, the Fourth People's Hospital of Nanning, Nanning, China
| | - Haibo Ding
- NHC Key Laboratory of AIDS Immunology (China Medical University), Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - Hongxia Wei
- Department of Infectious Disease, The Second Hospital of Nanjing, Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Ping Ma
- Department of Infectious Disease, the Affiliated Second Peoples' Hospital of the Nankai University, Tianjin, China
| | - Min Wang
- Institute of HIV/ AIDS, The First Hospital of Changsha, Changsha, China
| | - Shuiqing Liu
- Department of Infectious Diseases, Guiyang Public Health Clinical Center, Guiyang, China
| | - Yaokai Chen
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Xiaohong Chen
- Department of Infectious Diseases, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Qingxia Zhao
- Department of Infectious Diseases, Henan Infectious Disease Hospital, Zhengzhou, China
| | - Jianhua Yu
- Department of Infectious Diseases, XIXI Hospital of Hangzhou, Hangzhou, China
| | - Yuxia Song
- Department of Infectious Diseases, Xinjiang Uygur Autonomous Region Sixth People's Hospital, Xinjiang, China
| | - Hui Chen
- School of Biomedical Engineering, Capital Medical University, Beijing, China
| | - Hao Wu
- Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China
| | - Shanfang Qin
- Department of Infectious Diseases, Longtan Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China
| | - Linghua Li
- InInfectious Diseases Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
| |
Collapse
|
49
|
Martinez-Navio J, Desrosiers R, Fuchs S, Mendes D, Rakasz E, Gao G, Lifson J. How long is long-term? Delivery of anti-HIV antibodies using AAV vector. J Virus Erad 2019. [DOI: 10.1016/s2055-6640(20)30202-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
50
|
Chen X, Zhou F, Li X, Zhao C, Li W, Wu F, Yu J, Gao G, Li J, Li A, Ren S, Zhou C. Folate receptor-positive circulating tumour cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|